Vonaprument for Age-Related Macular Degeneration

(AiiM OLE Trial)

Not yet recruiting at 6 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Annexon, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.

Who Is on the Research Team?

CT

Clinical Trials

Principal Investigator

Annexon, Inc.

Are You a Good Fit for This Trial?

This trial is for people with dry age-related macular degeneration who have geographic atrophy and previously participated in a related ANX007 study. Participants must meet certain health requirements set by the researchers.

Inclusion Criteria

I have dry AMD with GA and completed the ARCHER II study without stopping treatment early.

Exclusion Criteria

Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.

What Are the Treatments Tested in This Trial?

Interventions

  • Vonaprument

Trial Overview

The study is testing the long-term safety of vonaprument, given as injections into the eye, in people with this type of vision loss. All participants receive the treatment; there is no placebo group.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: VonaprumentExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Annexon, Inc.

Lead Sponsor

Trials
14
Recruited
1,500+